Skip to content

Ultrasound-guided Regional Anesthesia vs Local Infiltration Anesthesia With Dexmedetomidine and Ropivacaine

Dexmedetomidine as Adjunct Medication to Local Infiltration Anesthesia (LIA) vs Ultrasound-Guided Regional Anesthesia (USRA) in Regard to Patients' Need for Opioids, Wellbeing, Satisfaction, and Knee Functionality in Knee-endoprosthetics

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04697537
Enrollment
50
Registered
2021-01-06
Start date
2021-02-01
Completion date
2021-04-09
Last updated
2021-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative, Anesthesia, Local, Gonarthrosis

Brief summary

Evaluation of the Impact of dexmedetomidine as an adjunct for local infiltrations analgesia and ultrasound-based regional anaesthesia as pain medication in regard to patients' opioid need the first 48 hours after the total knee replacement operation.

Detailed description

Evaluation of the Impact of dexmedetomidine as an adjunct for local infiltrations analgesia and ultrasound-based regional anaesthesia as pain medication in regard to patients' opioid need the first 48 hours after the total knee replacement operation. Secondary objectives are: Pain assesment, Pain medication necessary, functionality of the prothesis, satisfaction, wellbeing, postoperative discomforts, complications (delirium, allergic reactions, cardiopulmonary decompensation), procedure specific time.

Interventions

DRUGUltrasound guided regional anesthesia

Applied perineurally preoperatively ultrasound guided regional anesthesia

Applied in the wound intraoperatively from the orthopedics

Sponsors

Medical University of Graz
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Adult * non pregnant * patients with gonarthrosis who have given written consent for participation

Exclusion criteria

* Age below 18 years * pregnancy * breast-feeding patients * allergies against study medication * missing or denied written consent

Design outcomes

Primary

MeasureTime frameDescription
Need of opioid consumption in oral morphine equivalent48 hours postoperativelyconsumed opioids in mg of oral morphine equivalent

Secondary

MeasureTime frameDescription
Pain medication necessary5 days postoperatively or until dischargeNeed of opioid consumption in mg of oral morphine equivalent up to the 5th postoperative day
Functionality of the prothesis - OKS (Oxford Knee Score)5 days postoperatively or until dischargeAccording to physical examination by the Oxford Knee Score (minimum 0, maximum 48) (higher score means better outcome)
Functionality of the prothesis- KOOS (Knee Injury and Osteoarthritis Outcome Score)5 days postoperatively or until dischargeAccording to physical examination by the orthopedics score KOOS (minimum 0, maximum 100) (higher score means better outcome)
Pain assesment5 days postoperatively or until dischargePain experienced by patients according to self-assesment according to NRS (Numeric rating scale) (minimum 0, maximum 10) (higher score means worse outcome)
Functionality of the prothesis- G-FJS (German Forgotten Joint Score)5 days postoperatively or until dischargeAccording to physical examination by the orthopedics score G-FJS (minimum 0, maximum 100) (higher score means better outcome)
Complications5 days postoperatively or until dischargeIncidence of complications in total (e.g. delirium, allergic reactions, cardiopulmonary decompensation)
procedure specific timeduring surgerytime of the operation
Functionality of the prothesis - WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index)5 days postoperatively or until dischargeAccording to physical examination by the orthopedics score WOMAC (minimum 0, maximum 96) (higher score means worse outcome)

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026